JP2003516417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516417A5 JP2003516417A5 JP2001543578A JP2001543578A JP2003516417A5 JP 2003516417 A5 JP2003516417 A5 JP 2003516417A5 JP 2001543578 A JP2001543578 A JP 2001543578A JP 2001543578 A JP2001543578 A JP 2001543578A JP 2003516417 A5 JP2003516417 A5 JP 2003516417A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- patient
- compound according
- compound
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 22
- 150000001371 alpha-amino acids Chemical class 0.000 description 8
- 235000008206 alpha-amino acids Nutrition 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 4
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 4
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 229910052739 hydrogen Chemical group 0.000 description 3
- 239000001257 hydrogen Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- -1 aliphatic amines Chemical class 0.000 description 2
- 150000003975 aryl alkyl amines Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45548399A | 1999-12-06 | 1999-12-06 | |
| US09/455,483 | 1999-12-06 | ||
| PCT/CA2000/001445 WO2001042281A1 (en) | 1999-12-06 | 2000-12-06 | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516417A JP2003516417A (ja) | 2003-05-13 |
| JP2003516417A5 true JP2003516417A5 (enExample) | 2008-01-24 |
Family
ID=23808998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001543578A Withdrawn JP2003516417A (ja) | 1999-12-06 | 2000-12-06 | 糸球体濾過異常、動脈管開存、および骨粗鬆症治療に用いる組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7442763B2 (enExample) |
| EP (1) | EP1244693B1 (enExample) |
| JP (1) | JP2003516417A (enExample) |
| AT (1) | ATE298346T1 (enExample) |
| AU (1) | AU784630B2 (enExample) |
| CA (1) | CA2396739A1 (enExample) |
| DE (1) | DE60020997T2 (enExample) |
| ES (1) | ES2246915T3 (enExample) |
| MX (1) | MXPA02005626A (enExample) |
| NZ (1) | NZ520762A (enExample) |
| WO (1) | WO2001042281A1 (enExample) |
| ZA (1) | ZA200205795B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| DE60020997T2 (de) | 1999-12-06 | 2006-05-24 | Hopital Sainte-Justine, Montreal | Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose |
| EP1467738A1 (en) * | 2001-10-08 | 2004-10-20 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| DE60222168T2 (de) * | 2001-10-31 | 2008-05-15 | Medical Research Council | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie |
| US7414029B2 (en) | 2002-05-23 | 2008-08-19 | Theratechnologies, Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| EP1878741A3 (en) * | 2002-05-23 | 2008-02-20 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| US20040023853A1 (en) * | 2002-05-23 | 2004-02-05 | Peri Krishna G. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| WO2004073589A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4) |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019120D0 (en) * | 1990-09-01 | 1990-10-17 | Beecham Group Plc | Novel compounds |
| US5508384A (en) * | 1992-09-10 | 1996-04-16 | New York University | Polypeptide derived from a popamine receptor, and compositions and methods thereof |
| JP3908271B2 (ja) * | 1993-03-05 | 2007-04-25 | エピミューン，インコーポレイティド | Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用 |
| US5869281A (en) | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| AU685187B2 (en) * | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
| WO1995029193A2 (en) * | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| WO1996006856A1 (en) * | 1994-08-31 | 1996-03-07 | Robert Webber | Dopamine receptor peptides and anti-peptide antibodies |
| MX9703988A (es) * | 1994-12-12 | 1998-02-28 | Omeros Med Sys Inc | SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO. |
| CA2211176A1 (en) | 1995-01-25 | 1996-08-01 | Cor Therapeutics, Inc. | Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US5877155A (en) * | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| BR9708220A (pt) * | 1996-03-21 | 2000-01-04 | Epimmune Inc | Peptìdios de ligação hla-a2.1 e seus usos |
| WO1998010651A1 (en) * | 1996-09-12 | 1998-03-19 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US5955575A (en) * | 1997-12-22 | 1999-09-21 | Hopital Sainte-Justine | Antagonists of G-protein-coupled receptor |
| AUPP320998A0 (en) * | 1998-04-27 | 1998-05-21 | Walter And Eliza Hall Institute Of Medical Research, The | Tyrosine phosphatase IA-2 T-cell epitopes |
| US6984719B1 (en) * | 1998-09-17 | 2006-01-10 | Hospital Sainte-Justine | Peptide antagonists of prostaglandin F2α receptor |
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| DE60020997T2 (de) | 1999-12-06 | 2006-05-24 | Hopital Sainte-Justine, Montreal | Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose |
-
2000
- 2000-12-06 DE DE60020997T patent/DE60020997T2/de not_active Expired - Fee Related
- 2000-12-06 MX MXPA02005626A patent/MXPA02005626A/es unknown
- 2000-12-06 AT AT00984691T patent/ATE298346T1/de not_active IP Right Cessation
- 2000-12-06 JP JP2001543578A patent/JP2003516417A/ja not_active Withdrawn
- 2000-12-06 ES ES00984691T patent/ES2246915T3/es not_active Expired - Lifetime
- 2000-12-06 NZ NZ520762A patent/NZ520762A/en active Application Filing
- 2000-12-06 CA CA002396739A patent/CA2396739A1/en not_active Abandoned
- 2000-12-06 WO PCT/CA2000/001445 patent/WO2001042281A1/en not_active Ceased
- 2000-12-06 EP EP00984691A patent/EP1244693B1/en not_active Expired - Lifetime
- 2000-12-06 AU AU21340/01A patent/AU784630B2/en not_active Ceased
-
2002
- 2002-06-04 US US10/162,004 patent/US7442763B2/en not_active Expired - Lifetime
- 2002-07-19 ZA ZA200205795A patent/ZA200205795B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2620111T3 (es) | Análogos de glucagón | |
| US9073963B2 (en) | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor | |
| JPH10330397A (ja) | サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法 | |
| TW202317604A (zh) | 用於治療遺傳性血鐵沉積症之鐵調素模擬物 | |
| JPS61118400A (ja) | 成長ホルモン放出性因子類似体及びその製造方法 | |
| ES2328334T3 (es) | Polipeptido y heterodimero de hormona glicoproteica similar a beta. | |
| JP2003516417A5 (enExample) | ||
| JP2018530590A (ja) | 表皮水疱症の処置のための方法及び組成物 | |
| JP3786533B2 (ja) | ペプチド及び骨形成促進剤 | |
| JP3280021B2 (ja) | 骨吸収を阻害する化合物及び組成物 | |
| EP1244693B1 (en) | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis | |
| US10434135B2 (en) | Pharmaceutical composition for preventing or treating arthritis | |
| WO2006041205A1 (ja) | 血管形成促進剤 | |
| JP5529014B2 (ja) | 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体 | |
| US20240285737A1 (en) | Improved methods of treatment using immunogenic peptides | |
| JP7123399B2 (ja) | タクロリムスのコンジュゲート、その組成物およびその使用 | |
| JPWO2014119753A1 (ja) | マイオスタチン阻害ペプチド | |
| KR20000070542A (ko) | Ⅱ형 콜라겐에 특이적인 ｔ 세포 에피토프를 포함하는 펩티드 | |
| JP2005082489A6 (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
| JP2005082489A (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
| ES2347245T3 (es) | Peptidos fisiologicamente activos y farmacos que contienen los mismos. | |
| JPH0539299A (ja) | 新規なカルシトニン | |
| WO2025122594A1 (en) | Improved methods and compositions for the treatment of pemphigus or pemphigoid disease | |
| WO2008077938A1 (en) | Modulators of talin/integrin association and use thereof | |
| JP2000159795A (ja) | ペプチド誘導体 |